Analysts are weighing in this afternoon on Gilead Sciences, Inc. (NASDAQ:GILD), after the U.S. pharmaceutical giant reported second-quarter results that surpassed analysts’ expectations on the strength of strong sales for its hepatitis C treatments. In reaction, Gilead shares are up 3.26% to $116.76 in after-hours trading.

J.P. Morgan analyst Cory Kasimov commented: “As has become the norm, the HCV franchise drove the top-line with $4.9B in total sales, easily surpassing consensus of $4.4B. For the second time this year, GILD increased FY15 net product sales guidance to $29-$30B vs. JPMe of $29.6B (we had considered prior guidance of $28B-$29B to be slightly conservative). At the end of 1Q15, Gilead had $14.7B of cash and cash equivalents, and generated $5.7B in operating cash flows during the quarter.”


The analyst rates Gilead stock a Buy with a price target of $115.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Mark Schoenebaum has a total average return of 20.4% and a 77.8% success rate. Schoenebaum has a 40% average return when recommending GILD, and is ranked #1049 out of 3712 analysts.

Out of the 20 analysts polled by TipRanks, 18 rate Gilead Sciences stock a Buy, 1 rates the stock a Hold and 1 recommends Sell. With a return potential of 9.1%, the stock’s consensus target price stands at $123.35.

Don’t be late to the party – Click Here to see what 4500 Wall Street Analysts say about your stocks.